Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Da Hae Jung
 -- 2443 2022-08-04 18:05:40 |
2 format corrected.
Beatrix Zheng
 + 85 word(s) 2528 2022-08-05 06:10:31 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Jung, D.H.;  Son, G.;  Kwon, O.;  Chang, K.;  Moon, C. Body Fluid Biomarkers in Alzheimer’s Disease. Encyclopedia. Available online: https://encyclopedia.pub/entry/25865 (accessed on 17 November 2024).
Jung DH,  Son G,  Kwon O,  Chang K,  Moon C. Body Fluid Biomarkers in Alzheimer’s Disease. Encyclopedia. Available at: https://encyclopedia.pub/entry/25865. Accessed November 17, 2024.
Jung, Da Hae, Gowoon Son, Oh-Hoon Kwon, Keun-A Chang, Cheil Moon. "Body Fluid Biomarkers in Alzheimer’s Disease" Encyclopedia, https://encyclopedia.pub/entry/25865 (accessed November 17, 2024).
Jung, D.H.,  Son, G.,  Kwon, O.,  Chang, K., & Moon, C. (2022, August 04). Body Fluid Biomarkers in Alzheimer’s Disease. In Encyclopedia. https://encyclopedia.pub/entry/25865
Jung, Da Hae, et al. "Body Fluid Biomarkers in Alzheimer’s Disease." Encyclopedia. Web. 04 August, 2022.
Body Fluid Biomarkers in Alzheimer’s Disease
Edit
This entry is adapted from the peer-reviewed paper 10.3390/pharmaceutics14081532

Alzheimer’s disease (AD) is an irreversibly progressive neurodegenerative disease afflicting the elderly, accompanied by devastating cognitive and memory impairment caused by characteristic neuronal and synaptic loss and cortical and hippocampal atrophy. It is hallmarked by the accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles. The underlying mechanisms contributing to the development of the disease remain elusive and controversial. Despite the advancement in understanding the mechanism of pathogenesis, clinical trials have been unsuccessful and provided no relief from disease progression, only slowing the progression. Recent FDA-approved anti-amyloid therapy aducanumab highlights that it is effective for patients with very mild, biomarker-proven AD. Therefore, there is an urgent need to develop a more accessible biomarker screening test using less invasive and cost-effective body fluid biomarkers. These diagnostics will serve as the first line of effective AD therapies before extensive pathophysiological brain devastation occurs.

Alzheimer’s disease nasal discharge fluid body fluid biomarker diagnosis non-invasive peripheral

1. Conventional AD Body Fluid Biomarkers

A biomarker indicates the change of cells and tissues, which illustrates altered body conditions [1]. In the clinics, biomarkers represent the pathological status and monitor the disease progression. Appropriate methods to detect disease biomarkers in living patients are important for establishing early intervention times and evaluating clinical therapeutic efficacy.
Given that Alzheimer’s disease (AD) is progressive and incurable, an ideal method to detect AD biomarkers is required for AD-specific early detection, economic accessibility, and non-invasive sample collection [2]. The neuropsychological test is a worldwide and classic method to identify cognitive impairment, but multiple profiling is demanded to confirm AD from other neurodegenerative diseases. Although brain imaging (e.g., fMRI, FDG-, amyloid-, and tau-PET) observes disease-specific pathophysiology, the patients may find it difficult to perform neuroimaging tests due to their repeatedly high costs. Recently, observing amyloid-β and tau as biomarkers in CSF and plasma are approved by NIA-AA [3]. In addition to CSF and blood, body fluids that can closely reflect the patient’s pathological condition have been studied. Figure 1 illustrates body fluids that have the potential to be matrices of biomarker detection.
/media/item_content/202208/62ec9751be7f3pharmaceutics-14-01532-g001.png
Figure 1. Body fluids for the identification of potential biomarkers for AD. Sample type, organ, sampling method (from above).

1.1. CSF

CSF is a clear and colorless body fluid in the subarachnoid space and circulates within the ventricular system of the brain and spinal cord to supply nutrients and chemicals, remove waste products, and provide the brain immunological protection and mechanical support [4][5]. CSF is produced in the choroid plexus of the brain’s ventricles and reabsorbed into venous sinus blood via the arachnoid granulations. The total volume of CSF is approximately 125–160 mL. CSF is replaced four to five times and regenerates about 500 mL every day [6]. Since CSF reflects biochemical and environmental changes within the central nervous system, CSF is an ideal and useful candidate for detecting potential neuropathology biomarkers [7][8]. CSF is usually obtained by a procedure called a lumbar puncture. The standardized collection protocol of lumbar puncture is carried out under sterile conditions by inserting a needle into the subarachnoid space between the third and fifth lumbar vertebrae [9].
NIA-AA and International Working Group (IWG) 2 have recognized the significance of CSF biomarkers, including Aβ42, T-tau, and P-tau, and incorporated them into diagnostic criteria for AD and MCI [10][11][12]. In AD, Aβ42 concentration and Aβ42/Aβ40 ratio are reduced, and T-tau and P-tau concentrations increase in CSF [4][13][14][15].
Although lumbar puncture is the most common and recommended method for CSF collection, there are some issues: lumbar puncture results in discomfort and pain due to the larger and longer needle and the possibility of CSF contamination by anesthesia. In addition, it is very difficult and expensive to perform the procedure on the subjects repeatedly [9].

1.2. Blood (Plasma and Serum)

Blood plasma is the liquid component in which blood cells are suspended [16]. It delivers nutrients and oxygen to the cells and transports cellular metabolic products. It amounts to about 55% of the total blood volume and is mostly water. Blood plasma is circulated through the body via blood vessels by the pumping of the heart. Functions of blood plasma are maintenance of the blood pressure, pH, immunity, and transportation of electrolytes, nutrients, clotting factors, carbon dioxide, oxygen, other waste products, and excretory proteins.
Blood serum is blood plasma without clotting factors such as fibrinogens [16]. Blood serum includes all electrolytes, antibodies, antigens, hormones, and other substances, except white blood cells, red blood cells, platelets, and clotting factors [17][18]. Blood serum is obtained by coagulation, which allows for clotting of the blood. Both plasma and serum are commonly used for proteomic analysis.
Blood samples are collected by venipuncture, and the protocol commonly used is based on the Human Plasma Proteome Project (HPPP) by the Human Proteome Organization (HUPO) and the National Institute of Health [19][20]. 
The conventional biomarkers of AD, such as Aβ42, Aβ40, T-tau, and P-tau, are commonly utilized as potential candidate screening molecules in blood samples because they can pass the blood–brain barrier (BBB) [21][22][23]. However, the BBB breaks down in AD patients, which leads to an accumulation of blood-derived neurotoxic proteins in the brain [24].
Biomarkers for neuropathology from blood samples have been controversial because blood communicates with the brain through the BBB, lymphatic vessel, and lymphatic system, which indirectly interchange the materials and substances from the brain into blood, resulting in lower sensitivity and specificity than CSF [21][25][26][27].

2. Novel Peripheral Body Fluid Biomarkers

Recent research has shown that other peripheral body fluids, such as nasal discharge, tear, saliva, and urine, may represent a potential source of biomarkers for neurodegenerative diseases. These peripheral body fluids have advantages over CSF or blood since the collection methods are less invasive and enable low-cost biomonitoring.

2.1. Nasal Discharge

The occurrence of olfactory deficits, named anosmia or hyposmia, in AD has been characterized for decades, and often these deficits precede the cognitive decline [28][29][30][31]. Olfactory neuropathology is the cause of olfactory dysfunction, and structural and functional evidence supports this view, including abnormal APP processing and neuroinflammation [32][33][34][35][36]. The central olfactory processing regions, such as entorhinal and transentorhinal areas, olfactory bulb, and other medial temporal lobes, anatomically overlap with the regions involved in early AD pathology [28][37][38]. AD postmortem and antemortem studies revealed that the olfactory system shows classic AD hallmarks such as intracellular neurofibrillary tau tangles and amyloid plaques [39][40][41][42][43]. In particular, nasal discharge surrounds the olfactory system and captures the neuropathology occurring in the system, emerging as a potential matrix of fluid biomarkers.
Nasal discharge is a slippery and gelatinous fluid produced by mucous membranes in the olfactory mucosa. Nasal discharge is 95% water, glycoproteins, proteoglycans, lipids, proteins, and DNA. The purpose of nasal discharge is to protect the olfactory epithelium (OE) and the respiratory system by blocking the infections of pathogenic antigens. Nasal discharge fluids serve to humidify and clean inhale air and provide proteins of the innate immune system. Additionally, nasal discharge fluids trap and dissolve odorants for the olfactory receptor neurons.
Since the olfactory system is exposed to the external environment, the collection of nasal discharge fluid is easily accessible and non-invasive.
Early studies identified the presence of amyloid-β peptide and amyloid precursor proteins (APP) in postmortem AD patients’ olfactory mucosa samples [40][44]. Aggregation of amyloid-β expression was detected in 71% of AD cases, 22% in normal cases, and 14% in other neurodegenerative disease cases [45]. Biopsy examination identified Aβ expression from the normal, MCI, and AD subjects [46]. Sampling human olfactory environment for AD-related research advanced from taking autopsy or biopsy samples to collecting human nasal discharge. A study collected nasal smears by swabbing from multiple nasal areas, such as the common nasal meatus, inferior concha, middle nasal meatus, and olfactory cleft [47]. Subsequent studies analyzed Aβ expression in nasal discharge fluid by immunoassay and proved that the level of oligomeric Aβ in nasal discharge was higher in AD than normal [48][49]. A 3-year longitudinal study by Yoo et al. confirmed that the presence of oligomeric Aβ could predict the cognitive decline progression [48].
Similarly, early studies used the histopathological method to detect T-tau in postmortem and antemortem samples of AD patients’ olfactory systems [41][50]. Later, immuno-histochemical studies demonstrated that tau pathology in the olfactory system correlated with AD pathology progression [39][51]. ELISA-analysis of nasal smear swabs indicated that P-tau/T-tau ratios were more significant in AD than control [47][52].
Non-core AD hallmark biomarkers have also been identified in the olfactory system. Expression of α-synuclein was identified in postmortem OE of AD sample [45]. A study showed increased microRNA-206 in AD patients’ OE through qRT-PCR [53]. Proteome analysis was done on nasal discharge samples from young, healthy groups and elderly groups, and identified a list of associated proteins with age variability [54]. However, little is known about the molecular machinery responsible for mucus proteome and its changes in neurodegenerative diseases.

2.2. Tears

Tears have a high protein content and have been widely investigated for biomarker studies for ocular diseases and diabetes [55][56]. Major tear proteins, lipocalin-1 and lactotransferrin, are involved in the inflammatory and immune processes [55][57]. Researchers studying neurodegenerative diseases have also hypothesized that neuroinflammation could be reflected in tear proteins due to the extension of the central nervous system. Recent AD studies conducted tear analyses and discovered the potential of tear biomarkers in AD.
Gijs et al. measured Aβ42 in tears using multiplex immunoassays and found the Aβ42 levels changed with increasing AD stage with an area under the curve (AUC) of 0.725 [58]. Other Aβ peptides, Aβ38 and Aβ40, were also detected in their subsequent study [59]. Recently, Wang et al. developed a biosensor and detected variable Aβ42 levels in different age groups of healthy participants [60]. Gijs et al. also analyzed T-tau, and its levels were also able to discriminate between AD patients and healthy controls with an AUC of 0.81 [58][59]. Quantitative proteomic results profiled that lipocalin-1, dermcidin, lysozyme-C, and lacritin can serve AD biomarkers [61]. One LC/MS evaluation identified elongation initiation factor 4E (elF4E) uniquely in AD tear samples, and a PCR-based analysis showed elevated total microRNA abundance in AD patients’ tears and especially higher microRNA-200b-5p levels in tears of AD patients compared to healthy controls [62].

2.3. Saliva

Saliva is an easily accessible, non-invasive body fluid containing 98% water containing electrolytes, proteins, peptides, hormones, sugar, epithelial cells, white blood cells, enzymes, and lysozymes [63]. The functions of saliva are the protection and maintenance of oral mucosa, digestion, the perception of taste, and the control of microorganisms [64][65]. Saliva is secreted from three major salivary glands, named the sublingual, submandibular, and parotid, and they are innervated by the cranial and facial nerves [66]. The direct innervation of the glossopharyngeal nerve through the otic ganglion suggests that saliva can be a promising candidate of biomarker source for assessing pathological physiologies of the nervous system [67].
Several various methods for collecting saliva have been described in the past years. In 2007, the World Health Organization and International Agency for Research on Cancer described the protocol for saliva proteomics [68].
In the last few years, various studies have detected increased Aβ42 in AD patients’ saliva using sandwich and nanobead ELISAs. Bermejo-Pareja et al. analyzed saliva samples by immunoassays and identified a statistically significant increase in saliva Aβ42 levels in mild AD patients than normal control [69]. Subsequent studies similarly showed elevated Aβ42 levels in AD saliva samples [70][71][72]. In contrast to these findings, other results showed no detection of Aβ42 or Aβ40 in saliva with immunoassays [67][69][73]. On the other hand, a recent study demonstrated decreased Aβ42 level in AD patients’ saliva [74]. Some preliminary tau investigation was carried out in the 2010s, and Shi et al. reported an increased P-tau/T-tau ratio in patients with AD compared to healthy controls [67]. A subsequent study also confirmed this increased P-tau/T-tau ratio in AD versus healthy controls [75]. In contradiction with these findings, results demonstrated no significant difference in salivary T-tau between AD and mild cognitive impairment or healthy controls [76].
A growing number of studies have examined possible biomarker candidates other than Aβ and tau peptides. Lactoferrin, for instance, is a pleiotropic protein with several immunological properties, including antibacterial, antiviral, antioxidant, and anti-inflammatory functions [77][78]. The first investigations on salivary lactoferrin found a decreased lactoferrin level in AD patients’ saliva compared to healthy controls [79]. A more recent study supported this finding by comparing salivary lactoferrin levels with amyloid-PET neuroimaging data [80]. Acetylcholinesterase degrades acetylcholine neurotransmitters released into the synaptic cleft and terminates acetylcholine neurotransmission, and PET study results demonstrated decreased acetylcholinesterase catalytic activity in AD patients’ brain regions [81][82][83]. An initial report on the salivary acetylcholinesterase activity was carried out by Sayer et al. and showed a significant decrease in AD patients [84]. Further studies also suggested a reduced salivary acetylcholinesterase activity in AD patients [85][86]. Protein carbonyl levels result from protein oxidation, and multiple studies examined elevated protein carbonyls in brain regions of AD patients [87][88]. One study evaluated and identified protein carbonyl levels in saliva of AD patients and healthy controls [89]. Metabolomics is an emerging research technique used in various research fields to identify metabolites within a target sample. Yilmaz et al. analyzed saliva samples from healthy control, mild cognitive impairment sufferers, and AD patients. They profiled multiple metabolites that changed significantly in the saliva of MCI and AD patients compared to healthy controls [90].

2.4. Urine

Urine contains thousands of proteins, mostly metabolic wastes, and is currently actively utilized to study pregnancy, aging, and kidney diseases [91][92]. Nevertheless, for many years urine has been neglected as a promising source of biomarkers for studying AD since there is little agreement on urine reflecting the changes occurring in the brain due to the BBB and glomerular filtration. However, several studies have indicated the potential of urinary biomarkers in neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s disease [93][94][95].
More importantly, urine collection does not require special equipment and can be repeated without discomfort to subjects. The Human Kidney and Urine Proteome Project (HKUPP) in 2005 and European Kidney and Urine Proteomics (EuroKUP) in 2008 were initiated to promote proteomics research, and they together have achieved the establishment of a standard protocol for urine collection and storage [96][97][98][99].
Initial report on detecting Aβ peptide in the urine of AD patients was carried out by Takata et al. by Western blot analysis and suggested that monomeric Aβ level may reflect the severity of AD [100]. A key question raised by Takata et al. was that they could not pinpoint the origin of Aβ in urine. A recent study developed an indirect competitive ELISA to measure Aβ42 in human urine samples [101].
Several studies have profiled potential urine protein biomarkers for AD. One study identified 15 proteins using LC/MS-MS and validated three proteins, SPP1, GSN, and IFGBP7, by ELISA [102]. Higher urinary AD7c-NTP, Alzheimer-associated neural thread protein, was demonstrated in another study [103]. Watanabe et al. analyzed AD patients’ urine samples and profiled 109 proteomes differentially expressed in AD and healthy controls [104]. Their subsequent study showed that apolipoprotein C3 levels in AD patients’ urine samples were higher in the AD and MCI groups than healthy controls using ELISA [105]. Urine also contains many metabolites, reflecting the gut microbiome theory in neurodegeneration studies [106][107][108]. One study recently examined urinary metabolome using NMR spectroscopy and UHPLC-MS and built a model that could discriminate between AD and healthy age-matched controls [109]. Another study developed a new screening approach using LC/MS and proposed that lipid peroxidation compounds may be potential predictors of early AD [110]. In addition, many studies reported microRNA in human urine samples and demonstrated that urinary microRNAs are relatively stable under various storage conditions, supporting their utility as urinary biomarkers [111][112][113].

References

  1. Baker, M. In biomarkers we trust? Nat. Biotechnol. 2005, 23, 297–304.
  2. Ray, P.; Le Manach, Y.; Riou, B.; Houle, T.T. Statistical evaluation of a biomarker. Anesthesiology 2010, 112, 1023–1040.
  3. Jack, C.R., Jr.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018, 14, 535–562.
  4. Blennow, K.; Hampel, H.; Weiner, M.; Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 131–144.
  5. Sakka, L.; Coll, G.; Chazal, J. Anatomy and physiology of cerebrospinal fluid. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2011, 128, 309–316.
  6. van Gool, A.J.; Hendrickson, R.C. The proteomic toolbox for studying cerebrospinal fluid. Expert Rev. Proteom. 2012, 9, 165–179.
  7. Lee, J.C.; Kim, S.J.; Hong, S.; Kim, Y. Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Exp. Mol. Med. 2019, 51, 1–10.
  8. Rosenberg, G.A. Chapter 4—Cerebrospinal Fluid: Formation, Absorption, Markers, and Relationship to Blood–Brain Barrier. In Primer on Cerebrovascular Diseases, 2nd ed.; Caplan, L.R., Biller, J., Leary, M.C., Lo, E.H., Thomas, A.J., Yenari, M., Zhang, J.H., Eds.; Academic Press: San Diego, CA, USA, 2017; pp. 25–31.
  9. Teunissen, C.E.; Petzold, A.; Bennett, J.L.; Berven, F.S.; Brundin, L.; Comabella, M.; Franciotta, D.; Frederiksen, J.L.; Fleming, J.O.; Furlan, R.; et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73, 1914–1922.
  10. Cummings, J.L.; Dubois, B.; Molinuevo, J.L.; Scheltens, P. International Work Group criteria for the diagnosis of Alzheimer disease. Med. Clin. N. Am. 2013, 97, 363–368.
  11. Dubois, B.; Feldman, H.H.; Jacova, C.; Dekosky, S.T.; Barberger-Gateau, P.; Cummings, J.; Delacourte, A.; Galasko, D.; Gauthier, S.; Jicha, G.; et al. Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6, 734–746.
  12. Dubois, B.; Feldman, H.H.; Jacova, C.; Hampel, H.; Molinuevo, J.L.; Blennow, K.; DeKosky, S.T.; Gauthier, S.; Selkoe, D.; Bateman, R.; et al. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Lancet Neurol. 2014, 13, 614–629.
  13. Oddo, S.; Caccamo, A.; Kitazawa, M.; Tseng, B.P.; LaFerla, F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol. Aging 2003, 24, 1063–1070.
  14. Braak, H.; Zetterberg, H.; Del Tredici, K.; Blennow, K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 2013, 126, 631–641.
  15. Zetterberg, H.; Wahlund, L.O.; Blennow, K. Cerebrospinal fluid markers for prediction of Alzheimer’s disease. Neurosci. Lett. 2003, 352, 67–69.
  16. Krebs, H.A. Chemical composition of blood plasma and serum. Annu. Rev. Biochem. 1950, 19, 409–430.
  17. Jacobs, J.M.; Adkins, J.N.; Qian, W.-J.; Liu, T.; Shen, Y.; Camp, D.G.; Smith, R.D. Utilizing Human Blood Plasma for Proteomic Biomarker Discovery. J. Proteome Res. 2005, 4, 1073–1085.
  18. Shen, Y.; Kim, J.; Strittmatter, E.F.; Jacobs, J.M.; Camp Ii, D.G.; Fang, R.; Tolié, N.; Moore, R.J.; Smith, R.D. Characterization of the human blood plasma proteome. Proteomics 2005, 5, 4034–4045.
  19. Rai, A.J.; Gelfand, C.A.; Haywood, B.C.; Warunek, D.J.; Yi, J.; Schuchard, M.D.; Mehigh, R.J.; Cockrill, S.L.; Scott, G.B.; Tammen, H.; et al. HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5, 3262–3277.
  20. Tuck, M.K.; Chan, D.W.; Chia, D.; Godwin, A.K.; Grizzle, W.E.; Krueger, K.E.; Rom, W.; Sanda, M.; Sorbara, L.; Stass, S.; et al. Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. J. Proteome Res. 2009, 8, 113–117.
  21. Hampel, H.; O’Bryant, S.E.; Molinuevo, J.L.; Zetterberg, H.; Masters, C.L.; Lista, S.; Kiddle, S.J.; Batrla, R.; Blennow, K. Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic. Nat. Rev. Neurol. 2018, 14, 639–652.
  22. Zetterberg, H. Blood-based biomarkers for Alzheimer’s disease-An update. J. Neurosci. Methods 2019, 319, 2–6.
  23. Milà-Alomà, M.; Suárez-Calvet, M.; Molinuevo, J.L. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Ther. Adv. Neurol. Disord. 2019, 12, 1756286419888819.
  24. Montagne, A.; Barnes, S.R.; Sweeney, M.D.; Halliday, M.R.; Sagare, A.P.; Zhao, Z.; Toga, A.W.; Jacobs, R.E.; Liu, C.Y.; Amezcua, L.; et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015, 85, 296–302.
  25. Zetterberg, H.; Blennow, K. From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer’s Disease. J. Alzheimers Dis. 2018, 64, S271–S279.
  26. Altuna-Azkargorta, M.; Mendioroz-Iriarte, M. Blood biomarkers in Alzheimer’s disease. Neurologia 2021, 36, 704–710.
  27. Balasa, R.; Barcutean, L.; Balasa, A.; Motataianu, A.; Roman-Filip, C.; Manu, D. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. Hum. Immunol. 2020, 81, 237–243.
  28. Murphy, C. Olfactory and other sensory impairments in Alzheimer disease. Nat. Rev. Neurol. 2019, 15, 11–24.
  29. Waldton, S. Clinical observations of impaired cranial nerve function in senile dementia. Acta Psychiatr. Scand. 1974, 50, 539–547.
  30. Doty, R.L.; Reyes, P.F.; Gregor, T. Presence of both odor identification and detection deficits in Alzheimer’s disease. Brain Res. Bull. 1987, 18, 597–600.
  31. Doty, R.L.; Hawkes, C.H.; Good, K.P.; Duda, J.E. Odor Perception and Neuropathology in Neurodegenerative Diseases and Schizophrenia. In Handbook of Olfaction and Gustation, 3rd ed.; Wiley Online Books, Doty, R.L., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2015; pp. 403–452.
  32. Son, G.; Jahanshahi, A.; Yoo, S.J.; Boonstra, J.T.; Hopkins, D.A.; Steinbusch, H.W.M.; Moon, C. Olfactory neuropathology in Alzheimer’s disease: A sign of ongoing neurodegeneration. BMB Rep. 2021, 54, 295–304.
  33. Kim, J.Y.; Rasheed, A.; Yoo, S.J.; Kim, S.Y.; Cho, B.; Son, G.; Yu, S.W.; Chang, K.A.; Suh, Y.H.; Moon, C. Distinct amyloid precursor protein processing machineries of the olfactory system. Biochem. Biophys. Res. Commun. 2018, 495, 533–538.
  34. Wesson, D.W.; Levy, E.; Nixon, R.A.; Wilson, D.A. Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer’s disease mouse model. J. Neurosci. 2010, 30, 505–514.
  35. Yoo, S.J.; Lee, J.H.; Kim, S.Y.; Son, G.; Kim, J.Y.; Cho, B.; Yu, S.W.; Chang, K.A.; Suh, Y.H.; Moon, C. Differential spatial expression of peripheral olfactory neuron-derived BACE1 induces olfactory impairment by region-specific accumulation of beta-amyloid oligomer. Cell Death Dis. 2017, 8, e2977.
  36. Son, G.; Steinbusch, H.W.; López-Iglesias, C.; Moon, C.; Jahanshahi, A. Severe histomorphological alterations in post-mortem olfactory glomeruli in Alzheimer’s disease. Brain Pathol. 2022, 32, e13033.
  37. Braak, H.; Braak, E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991, 1, 213–216.
  38. Masurkar, A.V.; Devanand, D.P. Olfactory Dysfunction in the Elderly: Basic Circuitry and Alterations with Normal Aging and Alzheimer’s Disease. Curr. Geriatr. Rep. 2014, 3, 91–100.
  39. Attems, J.; Lintner, F.; Jellinger, K.A. Olfactory involvement in aging and Alzheimer’s disease: An autopsy study. J. Alzheimers Dis. 2005, 7, 149–157.
  40. Crino, P.B.; Martin, J.A.; Hill, W.D.; Greenberg, B.; Lee, V.M.; Trojanowski, J.Q. Beta-Amyloid peptide and amyloid precursor proteins in olfactory mucosa of patients with Alzheimer’s disease, Parkinson’s disease, and Down syndrome. Ann. Otol. Rhinol. Laryngol. 1995, 104, 655–661.
  41. Hock, C.; Golombowski, S.; Muller-Spahn, F.; Peschel, O.; Riederer, A.; Probst, A.; Mandelkow, E.; Unger, J. Histological markers in nasal mucosa of patients with Alzheimer’s disease. Eur. Neurol. 1998, 40, 31–36.
  42. Attems, J.; Walker, L.; Jellinger, K.A. Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol. 2014, 127, 459–475.
  43. Franks, K.H.; Chuah, M.I.; King, A.E.; Vickers, J.C. Connectivity of Pathology: The Olfactory System as a Model for Network-Driven Mechanisms of Alzheimer’s Disease Pathogenesis. Front. Aging Neurosci. 2015, 7, 234.
  44. Struble, R.G.; Clark, H.B. Olfactory bulb lesions in Alzheimer’s disease. Neurobiol. Aging 1992, 13, 469–473.
  45. Arnold, S.E.; Lee, E.B.; Moberg, P.J.; Stutzbach, L.; Kazi, H.; Han, L.Y.; Lee, V.M.; Trojanowski, J.Q. Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann. Neurol. 2010, 67, 462–469.
  46. Ayala-Grosso, C.A.; Pieruzzini, R.; Diaz-Solano, D.; Wittig, O.; Abrante, L.; Vargas, L.; Cardier, J. Amyloid-aβ Peptide in olfactory mucosa and mesenchymal stromal cells of mild cognitive impairment and Alzheimer’s disease patients. Brain Pathol. 2015, 25, 136–145.
  47. Liu, Z.; Kameshima, N.; Nanjo, T.; Shiino, A.; Kato, T.; Shimizu, S.; Shimizu, T.; Tanaka, S.; Miura, K.; Tooyama, I. Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau. J. Alzheimers Dis. 2018, 62, 737–744.
  48. Yoo, S.J.; Son, G.; Bae, J.; Kim, S.Y.; Yoo, Y.K.; Park, D.; Baek, S.Y.; Chang, K.A.; Suh, Y.H.; Lee, Y.B.; et al. Longitudinal profiling of oligomeric Aβ in human nasal discharge reflecting cognitive decline in probable Alzheimer’s disease. Sci. Rep. 2020, 10, 11234.
  49. Kim, Y.H.; Lee, S.M.; Cho, S.; Kang, J.H.; Minn, Y.K.; Park, H.; Choi, S.H. Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease. Sci. Rep. 2019, 9, 4966.
  50. Lee, J.H.; Goedert, M.; Hill, W.D.; Lee, V.M.; Trojanowski, J.Q. Tau proteins are abnormally expressed in olfactory epithelium of Alzheimer patients and developmentally regulated in human fetal spinal cord. Exp. Neurol. 1993, 121, 93–105.
  51. Attems, J.; Jellinger, K.A. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin. Neuropathol. 2006, 25, 265–271.
  52. Passali, G.C.; Politi, L.; Crisanti, A.; Loglisci, M.; Anzivino, R.; Passali, D. Tau Protein Detection in Anosmic Alzheimer’s Disease Patient’s Nasal Secretions. Chemosens. Percept. 2015, 8, 201–206.
  53. Moon, J.; Lee, S.T.; Kong, I.G.; Byun, J.I.; Sunwoo, J.S.; Shin, J.W.; Shim, J.Y.; Park, J.H.; Jeon, D.; Jung, K.H.; et al. Early diagnosis of Alzheimer’s disease from elevated olfactory mucosal miR-206 level. Sci. Rep. 2016, 6, 20364.
  54. Yoshikawa, K.; Wang, H.; Jaen, C.; Haneoka, M.; Saito, N.; Nakamura, J.; Adappa, N.D.; Cohen, N.A.; Dalton, P. The human olfactory cleft mucus proteome and its age-related changes. Sci. Rep. 2018, 8, 17170.
  55. Zhou, L.; Zhao, S.Z.; Koh, S.K.; Chen, L.; Vaz, C.; Tanavde, V.; Li, X.R.; Beuerman, R.W. In-depth analysis of the human tear proteome. J. Proteom. 2012, 75, 3877–3885.
  56. Herber, S.; Grus, F.H.; Sabuncuo, P.; Augustin, A.J. Two-dimensional analysis of tear protein patterns of diabetic patients. Electrophoresis 2001, 22, 1838–1844.
  57. Comoglu, S.S.; Guven, H.; Acar, M.; Ozturk, G.; Kocer, B. Tear levels of tumor necrosis factor-alpha in patients with Parkinson’s disease. Neurosci. Lett. 2013, 553, 63–67.
  58. Gijs, M.; Nuijts, R.M.; Ramakers, I.; Verhey, F.; Webers, C.A.B. Differences in tear protein biomarkers between patients with Alzheimer’s disease and controls. Investig. Ophth. Vis. Sci. 2019, 60, 1744.
  59. Gijs, M.; Ramakers, I.H.G.B.; Visser, P.J.; Verhey, F.R.J.; van de Waarenburg, M.P.H.; Schalkwijk, C.G.; Nuijts, R.M.M.A.; Webers, C.A.B. Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. Sci. Rep. 2021, 11, 22675.
  60. Wang, Y.R.; Chuang, H.C.; Tripathi, A.; Wang, Y.L.; Ko, M.L.; Chuang, C.C.; Chen, J.C. High-Sensitivity and Trace-Amount Specimen Electrochemical Sensors for Exploring the Levels of beta-Amyloid in Human Blood and Tears. Anal. Chem. 2021, 93, 8099–8106.
  61. Kallo, G.; Emri, M.; Varga, Z.; Ujhelyi, B.; Tozser, J.; Csutak, A.; Csosz, E. Changes in the Chemical Barrier Composition of Tears in Alzheimer’s Disease Reveal Potential Tear Diagnostic Biomarkers. PLoS ONE 2016, 11, e0158000.
  62. Kenny, A.; Jimenez-Mateos, E.M.; Zea-Sevilla, M.A.; Rabano, A.; Gili-Manzanaro, P.; Prehn, J.H.M.; Henshall, D.C.; Avila, J.; Engel, T.; Hernandez, F. Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer’s disease. Sci. Rep. 2019, 9, 15437.
  63. Schenkels, L.C.; Veerman, E.C.; Nieuw Amerongen, A.V. Biochemical composition of human saliva in relation to other mucosal fluids. Crit. Rev. Oral Biol. Med. 1995, 6, 161–175.
  64. Lamy, E.; Mau, M. Saliva proteomics as an emerging, non-invasive tool to study livestock physiology, nutrition and diseases. J. Proteom. 2012, 75, 4251–4258.
  65. Vitorino, R.; Guedes, S.; Manadas, B.; Ferreira, R.; Amado, F. Toward a standardized saliva proteome analysis methodology. J. Proteom. 2012, 75, 5140–5165.
  66. Teresi, L.M.; Kolin, E.; Lufkin, R.B.; Hanafee, W.N. MR imaging of the intraparotid facial nerve: Normal anatomy and pathology. AJR Am. J. Roentgenol. 1987, 148, 995–1000.
  67. Shi, M.; Sui, Y.T.; Peskind, E.R.; Li, G.; Hwang, H.; Devic, I.; Ginghina, C.; Edgar, J.S.; Pan, C.; Goodlett, D.R.; et al. Salivary Tau Species are Potential Biomarkers of Alzheimer’s Disease. J. Alzheimers Dis. 2011, 27, 299–305.
  68. Rohleder, N.; Nater, U.M. Determinants of salivary alpha-amylase in humans and methodological considerations. Psychoneuroendocrinology 2009, 34, 469–485.
  69. Bermejo-Pareja, F.; Antequera, D.; Vargas, T.; Molina, J.A.; Carro, E. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer’s disease: A pilot study. BMC Neurol. 2010, 10, 108.
  70. Lee, M.; Guo, J.P.; Kennedy, K.; McGeer, E.G.; McGeer, P.L. A Method for Diagnosing Alzheimer’s Disease Based on Salivary Amyloid-beta Protein 42 Levels. J. Alzheimers Dis. 2017, 55, 1175–1182.
  71. Sabbagh, M.N.; Shi, J.; Lee, M.; Arnold, L.; Al-Hasan, Y.; Heim, J.; McGeer, P. Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer’s disease dementia from normal controls: Preliminary findings. BMC Neurol. 2018, 18, 155.
  72. McGeer, P.L.; Guo, J.P.; Lee, M.; Kennedy, K.; McGeer, E.G. Alzheimer’s Disease Can Be Spared by Nonsteroidal Anti-Inflammatory Drugs. J. Alzheimers Dis. 2018, 62, 1219–1222.
  73. Kim, C.B.; Choi, Y.Y.; Song, W.K.; Song, K.B. Antibody-based magnetic nanoparticle immunoassay for quantification of Alzheimer’s disease pathogenic factor. J. Biomed. Opt. 2014, 19, 051205.
  74. Tvarijonaviciute, A.; Zamora, C.; Ceron, J.J.; Bravo-Cantero, A.F.; Pardo-Marin, L.; Valverde, S.; Lopez-Jornet, P. Salivary biomarkers in Alzheimer’s disease. Clin. Oral Investig. 2020, 24, 3437–3444.
  75. Pekeles, H.; Qureshi, H.Y.; Paudel, H.K.; Schipper, H.M.; Gornistky, M.; Chertkow, H. Development and validation of a salivary tau biomarker in Alzheimer’s disease. Alzheimers Dement. 2019, 11, 53–60.
  76. Ashton, N.J.; Ide, M.; Scholl, M.; Blennow, K.; Lovestone, S.; Hye, A.; Zetterberg, H. No association of salivary total tau concentration with Alzheimer’s disease. Neurobiol. Aging 2018, 70, 125–127.
  77. Kruzel, M.L.; Zimecki, M.; Actor, J.K. Lactoferrin in a Context of Inflammation-Induced Pathology. Front. Immunol. 2017, 8, 1438.
  78. Mayeur, S.; Spahis, S.; Pouliot, Y.; Levy, E. Lactoferrin, a Pleiotropic Protein in Health and Disease. Antioxid. Redox Signal 2016, 24, 813–836.
  79. Carro, E.; Bartolomé, F.; Bermejo-Pareja, F.; Villarejo-Galende, A.; Molina, J.A.; Ortiz, P.; Calero, M.; Rabano, A.; Cantero, J.L.; Orive, G. Early diagnosis of mild cognitive impairment and Alzheimer’s disease based on salivary lactoferrin. Alzheimers Dement. 2017, 8, 131–138.
  80. Gonzalez-Sanchez, M.; Bartolome, F.; Antequera, D.; Puertas-Martin, V.; Gonzalez, P.; Gomez-Grande, A.; Llamas-Velasco, S.; Herrero-San Martin, A.; Perez-Martinez, D.; Villarejo-Galende, A.; et al. Decreased salivary lactoferrin levels are specific to Alzheimer’s disease. EBioMedicine 2020, 57, 102834.
  81. Whitehouse, P.J.; Price, D.L.; Clark, A.W.; Coyle, J.T.; DeLong, M.R. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10, 122–126.
  82. Jann, M.W. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy 2000, 20, 1–12.
  83. Rinne, J.O.; Kaasinen, V.; Jarvenpaa, T.; Nagren, K.; Roivainen, A.; Yu, M.; Oikonen, V.; Kurki, T. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 2003, 74, 113–115.
  84. Sayer, R.; Law, E.; Connelly, P.J.; Breen, K.C. Association of a salivary acetylcholinesterase with Alzheimer’s disease and response to cholinesterase inhibitors. Clin. Biochem. 2004, 37, 98–104.
  85. Bakhtiari, S.; Moghadam, N.B.; Ehsani, M.; Mortazavi, H.; Sabour, S.; Bakhshi, M. Can Salivary Acetylcholinesterase be a Diagnostic Biomarker for Alzheimer? J. Clin. Diagn. Res. 2017, 11, ZC58–ZC60.
  86. Boston, P.F.; Gopalkaje, K.; Manning, L.; Middleton, L.; Loxley, M. Developing a simple laboratory test for Alzheimer’s disease: Measuring acetylcholinesterase in saliva—A pilot study. Int. J. Geriatr. Psychiatry 2008, 23, 439–440.
  87. Suzuki, Y.J.; Carini, M.; Butterfield, D.A. Protein Carbonylation. Antioxid Redox. Signal 2009, 12, 323–325.
  88. Aksenov, M.Y.; Aksenova, M.V.; Butterfield, D.A.; Geddes, J.W.; Markesbery, W.R. Protein oxidation in the brain in Alzheimer’s disease. Neuroscience 2001, 103, 373–383.
  89. Su, H.; Gornitsky, M.; Geng, G.; Velly, A.M.; Chertkow, H.; Schipper, H.M. Diurnal variations in salivary protein carbonyl levels in normal and cognitively impaired human subjects. Age 2008, 30, 1–9.
  90. Yilmaz, A.; Geddes, T.; Han, B.; Bahado-Singh, R.O.; Wilson, G.D.; Imam, K.; Maddens, M.; Graham, S.F. Diagnostic Biomarkers of Alzheimer’s Disease as Identified in Saliva using 1H NMR-Based Metabolomics. J. Alzheimers Dis. 2017, 58, 355–359.
  91. Wu, J.Q.; Gao, Y.H. Physiological conditions can be reflected in human urine proteome and metabolome. Expert Rev. Proteomic 2015, 12, 623–636.
  92. Haubitz, M.; Wittke, S.; Weissinger, E.M.; Walden, M.; Rupprecht, H.D.; Floege, J.; Haller, H.; Mischak, H. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005, 67, 2313–2320.
  93. Nam, D.; Lee, J.Y.; Lee, M.; Kim, J.; Seol, W.; Son, I.; Ho, D.H. Detection and Assessment of alpha-Synuclein Oligomers in the Urine of Parkinson’s Disease Patients. J. Parkinson’s Dis. 2020, 10, 981–991.
  94. Wang, C.; Cui, Y.J.; Yang, J.C.; Zhang, J.R.; Yuan, D.C.; Wei, Y.; Li, Y.M.; Duo, Y.L.; Li, S.J.; Zhu, W.Y.; et al. Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer’s disease in patients with the apolipoprotein E epsilon 4 genotype. Biomarkers 2015, 20, 84–88.
  95. Luan, H.; Liu, L.F.; Meng, N.; Tang, Z.; Chua, K.K.; Chen, L.L.; Song, J.X.; Mok, V.C.; Xie, L.X.; Li, M.; et al. LC-MS-based urinary metabolite signatures in idiopathic Parkinson’s disease. J. Proteome Res. 2015, 14, 467–478.
  96. Mischak, H.; Kolch, W.; Aivaliotis, M.; Bouyssié, D.; Court, M.; Dihazi, H.; Dihazi, G.H.; Franke, J.; Garin, J.; Gonzalez de Peredo, A.; et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteom.-Clin. Appl. 2010, 4, 464–478.
  97. Yamamoto, T. The 4th Human Kidney and Urine Proteome Project (HKUPP) workshop. 26 September 2009, Toronto, Canada. Proteomics 2010, 10, 2069–2070.
  98. Yamamoto, T.; Langham, R.G.; Ronco, P.; Knepper, M.A.; Thongboonkerd, V. Towards standard protocols and guidelines for urine proteomics: A report on the Human Kidney and Urine Proteome Project (HKUPP) symposium and workshop, 6 October 2007, Seoul, Korea and 1 November 2007, San Francisco, CA, USA. Proteomics 2008, 8, 2156–2159.
  99. Zürbig, P.; Dihazi, H.; Metzger, J.; Thongboonkerd, V.; Vlahou, A. Urine proteomics in kidney and urogenital diseases: Moving towards clinical applications. Proteom.-Clin. Appl. 2011, 5, 256–268.
  100. Takata, M.; Nakashima, M.; Takehara, T.; Baba, H.; Machida, K.; Akitake, Y.; Ono, K.; Hosokawa, M.; Takahashi, M. Detection of amyloid beta protein in the urine of Alzheimer’s disease patients and healthy individuals. Neurosci. Lett. 2008, 435, 126–130.
  101. Wongta, A.; Hongsibsong, S.; Chantara, S.; Pattarawarapan, M.; Sapbamrer, R.; Sringarm, K.; Xu, Z.L.; Wang, H. Development of an Immunoassay for the Detection of Amyloid Beta 1-42 and Its Application in Urine Samples. J. Immunol. Res. 2020, 2020, 8821181.
  102. Yao, F.; Hong, X.; Li, S.; Zhang, Y.; Zhao, Q.; Du, W.; Wang, Y.; Ni, J. Urine-Based Biomarkers for Alzheimer’s Disease Identified Through Coupling Computational and Experimental Methods. J. Alzheimers Dis. 2018, 65, 421–431.
  103. Ku, B.D.; Kim, H.; Kim, Y.K.; Ryu, H.U. Comparison of Urinary Alzheimer-Associated Neural Thread Protein (AD7c-NTP) Levels Between Patients With Amnestic and Nonamnestic Mild Cognitive Impairment. Am. J. Alzheimers Dis. 2020, 35, 1533317519880369.
  104. Watanabe, Y.; Hirao, Y.; Kasuga, K.; Tokutake, T.; Semizu, Y.; Kitamura, K.; Ikeuchi, T.; Nakamura, K.; Yamamoto, T. Molecular Network Analysis of the Urinary Proteome of Alzheimer’s Disease Patients. Dement. Geriatr. Cogn. Dis. Extra 2019, 9, 53–65.
  105. Watanabe, Y.; Hirao, Y.; Kasuga, K.; Tokutake, T.; Kitamura, K.; Niida, S.; Ikeuchi, T.; Nakamura, K.; Yamamoto, T. Urinary Apolipoprotein C3 Is a Potential Biomarker for Alzheimer’s Disease. Dement. Geriatr. Cogn. Dis. Extra 2020, 10, 94–104.
  106. Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-gut microbiota metabolic interactions. Science 2012, 336, 1262–1267.
  107. Vogt, N.M.; Kerby, R.L.; Dill-McFarland, K.A.; Harding, S.J.; Merluzzi, A.P.; Johnson, S.C.; Carlsson, C.M.; Asthana, S.; Zetterberg, H.; Blennow, K.; et al. Gut microbiome alterations in Alzheimer’s disease. Sci. Rep. 2017, 7, 13537.
  108. Giau, V.V.; Wu, S.Y.; Jamerlan, A.; An, S.S.A.; Kim, S.Y.; Hulme, J. Gut Microbiota and Their Neuroinflammatory Implications in Alzheimer’s Disease. Nutrients 2018, 10, 1765.
  109. Kurbatova, N.; Garg, M.; Whiley, L.; Chekmeneva, E.; Jimenez, B.; Gomez-Romero, M.; Pearce, J.; Kimhofer, T.; D’Hondt, E.; Soininen, H.; et al. Urinary metabolic phenotyping for Alzheimer’s disease. Sci. Rep. 2020, 10, 21745.
  110. Pena-Bautista, C.; Vigor, C.; Galano, J.M.; Oger, C.; Durand, T.; Ferrer, I.; Cuevas, A.; Lopez-Cuevas, R.; Baquero, M.; Lopez-Nogueroles, M.; et al. New screening approach for Alzheimer’s disease risk assessment from urine lipid peroxidation compounds. Sci. Rep. 2019, 9, 14244.
  111. Mall, C.; Rocke, D.M.; Durbin-Johnson, B.; Weiss, R.H. Stability of miRNA in human urine supports its biomarker potential. Biomark. Med. 2013, 7, 623–631.
  112. Seol, W.; Kim, H.; Son, I. Urinary Biomarkers for Neurodegenerative Diseases. Exp. Neurobiol. 2020, 29, 325–333.
  113. Cheng, L.; Sun, X.; Scicluna, B.J.; Coleman, B.M.; Hill, A.F. Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. Kidney Int. 2014, 86, 433–444.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Da Hae Jung
,
Gowoon Son
,
Oh-Hoon Kwon
,
Keun-A Chang
,
Cheil Moon
View Times: 548
Revisions: 2 times (View History)
Update Date: 05 Aug 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback